Table 4.

Population dynamics of CD20+ B cells during treatment with rituximab: Absolute number in circulation.

Patient	CD20+ B cells x 109/liter of blood
	#1	#2	#3	#4	#5	#6
Pre-therapy	0.47	0.16	0.46	0.10	0.60	0.38
Week 1	0.15	0.42	0.25		0.48	0.37
Week 2	0.47	0.07		0.14	0.43	0.30
Week 3	0.43	0.12	0.44	0.10
Week 4	0.24		0.08		0.20	0.35
1 Month		0.10	0.35	0.05
2 Months	0.30		0.31	0.03	0.75	0.53
3 Months	0.33			0.05	0.54
4 Months	0.56	0.15	0.24		0.13	0.43
5 Months			0.36

The absolute number of B cells was calculated as the number of lymphocytes plus the number of monocytes (from the differential count performed by the clinical testing laboratory) multiplied by the % of PBMC that were shown to be CD20+ by flow cytometry, as presented in Table 3. The number of lymphocytes and monocytes was added to mimic the population of cells found in PBMC.